Netherlands-based Haga Teaching Hospital partners with physIQ and VitalConnect to continuously monitor cancer patients during treatment

Haga Teaching Hospital, physIQ,
and VitalConnect announced today that cancer patients are being enrolled
and monitored in a study that is evaluating how wearable biosensors and
artificial intelligence-based analytics can augment clinical care for
patients in treatment. The study is being funded by Janssen
Pharmaceuticals (a Johnson & Johnson Company). In the
investigator-initiated study, patients being treated with either
erythrocyte transfusion or chemotherapy, either with or without
immunotherapy, are provided VitalPatch® biosensors that collect and
stream physiological data via physIQ’s pinpointIQTM platform.
The goal of the study is to evaluate how continuous physiological data
coupled with sophisticated personalized analytics can provide early
clinical indication of adverse events sometimes associated with
anti-cancer treatment.

“Immunotherapy and other anti-cancer treatments offer great hope for
patients managing hematological diseases” said Dr. Martin Schipperus,
Chair of Hematology at Haga Teaching Hospital. “However, these same
powerful agents can also result in side effects that may impact
patients’ ability to tolerate treatment. By monitoring patients this
way, we hope to identify a novel approach to proactively identifying and
managing adverse events that may otherwise negatively impact patient
outcomes.”

Through the physIQ pinpointIQ
solution, clinical-grade vital signs stream continuously, 24/7, from
the VitalPatch biosensor to the cloud. Patients begin wearing the
biosensor several days prior to the treatment to allow the physIQ
artificial intelligence-based analytics to develop a pre-treatment
personalized baseline. Patients then continue to wear the VitalPatch,
both during and after treatment in the clinic. By comparing each patient
to their own personalized baseline, clinicians are able to continuously
monitor their physiological response throughout treatment and
afterwards, even when the patients have returned home.

“Artificial intelligence-based analytics and wearable biosensors hold
great promise for monitoring at-risk patient populations at home, at
work, in the clinic, and all places in between” said Dr. Stephen Ondra,
Chief Medical Officer of physIQ. “The oncology space is one that has
enormous unmet need with respect to how we deliver care and support
patients as they undergo and manage these potentially life-saving
therapies. Too often, patients must discontinue therapy because of
adverse events that could be avoided or minimized through early
detection. We are excited by the prospect of evolving the standard of
care to use personalized proactive information to improve outcomes.”

The pinpointIQ solution, its personalized analytics, and the VitalPatch
biosensor are being deployed in various clinical environments to support
clinicians caring for at-risk patient populations. The end-to-end
solution is also being provided to pharmaceutical and medical device
companies that are integrating real-world data sets into clinical
trials. With 14.1 million new cases annually worldwide1,
cancer is associated with some of the most pressing unmet needs in
healthcare. “Every year we see better treatments available in oncology
which is very encouraging,” added Schipperus, “but beyond drugs alone
there is need to improve the patient experience and we are excited about
the innovations now available to potentially improve how these patients
are cared for.”

About HagaZiekenhuis

The Haga Teaching Hospital in The Hague with Juliana Children’s Hospital
is since 2013 part of the Reinier Haga Group. A merger between Haga
Teaching Hospital (city of The Hague), Reinier de Graaf (city of Delft)
and LangeLand Hospital (city of Zoetermeer). We have selected with our
medical staff several themes in patient groups which includes
cardiovascular care and oncology. We opt for an integrated approach.
This includes both patient-driven outcomes and diagnosis of specific
processes, care paths, efficiency, innovation cycles and in the nearby
future cost analyzes.

About VitalConnect, Inc.

VitalConnect is a leader in wearable biosensor technology for wireless
patient monitoring in both hospital and remote patient populations.
VitalConnect leverages extensive expertise in biomedical engineering,
data analytics, chip design, and mobile and cloud software to create
technology that supports decision-making paradigms that achieve better
health and economic outcomes. VitalConnect’s products are designed for
use in a broad range of inpatient and outpatient settings, such as
hospital monitoring, post discharge care, cardiac monitoring and
pharmaceutical solutions. For more information: www.vitalconnect.com

About physIQ, Inc.

PhysIQ is a company dedicated to enabling proactive care delivery models
through pinpointIQ™, our highly scalable cloud-based platform for
personalized physiology analytics. Our FDA 510k-cleared data analytics
platform is designed to process multiple vital signs from wearable
sensors to create a personalized dynamic baseline for each individual.
By mapping vital sign relationships this way, physIQ’s analytics detect
subtle deviations that may be a precursor to disease exacerbation or
change in health. With applications in both healthcare and clinical
trial support, physIQ is transforming continuous physiological data into
insight for providers, health systems, payers, and pharmaceutical and
medical device companies. For more information, please visit www.physiq.com.
Follow us on Twitter and LinkedIn.

1 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005328/en/

Leave a Comment